Phio Pharmaceuticals CFO Carson Lisa Cabott forfeited 12,888 shares at $1.03 per share. The transaction left her with 81,112 shares and represented about 13.7% of her prior shares holding, showing the reported change in her Phio ownership position.
Key Highlights
- The transaction used SEC code F.
- Carson Lisa Cabott held 81,112 shares after the transaction.
- Carson Lisa Cabott forfeited 12,888 Phio Pharmaceuticals shares.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) recorded a forfeiture of 12,888 shares by Chief Financial Officer Carson Lisa Cabott. The transaction was priced at $1.03 per share.
$1.03 Share Forfeiture Reported in Form 4
The transaction occurred on Sep 11, 2026. Its SEC transaction code was F. Cabott was identified as Phio Pharmaceuticals Corp.’s chief financial officer. The reported transaction involved 12,888 shares at $1.03 per share. The recorded action concerns Cabott’s Phio Pharmaceuticals Corp. share position.
Post-Transaction Holding Stood at 81,112 Shares
Cabott owned 81,112 shares after the transaction. The forfeiture represented about 13.7% of her prior shares holding. The percentage is measured against the shares she held before the transaction, while 81,112 shares is the post-transaction amount reported.
FAQs
Q: How many Phio Pharmaceuticals shares did Carson Lisa Cabott forfeit?
A: Carson Lisa Cabott forfeited 12,888 Phio Pharmaceuticals shares. The filing reports the transaction at $1.03 per share on Sep 11, 2026, and identifies Cabott as Phio Pharmaceuticals Corp.’s chief financial officer.
Q: How many shares did the Phio Pharmaceuticals CFO retain?
A: Carson Lisa Cabott owned 81,112 Phio Pharmaceuticals shares after the transaction. She is identified as the company’s chief financial officer.
Q: What transaction code was used for the Phio Pharmaceuticals share forfeiture?
A: The Phio Pharmaceuticals share forfeiture carried SEC transaction code F. It represented about 13.7% of Chief Financial Officer Carson Lisa Cabott’s prior shareholding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.